

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁杰瑞

ALPHAMAB ONCOLOGY

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2024 ANNUAL REPORT

Reference is made to the annual report of Alphamab Oncology (the “**Company**”) for the year ended December 31, 2024 dated April 28, 2025 (the “**2024 Annual Report**”). Unless otherwise defined, the capitalized terms used herein shall have the same meanings as those set out in the 2024 Annual Report.

The board (the “**Board**”) of directors (“**Director(s)**”) of the Company would like to provide the following additional information on its Treasury Shares, the use of proceeds from the Global Offering and the Top-up Placing and the Post-IPO Share Award Scheme.

1. Treasury Shares

The Company has not yet determined on the intended use of the Treasury Shares and will utilize them as permitted under the Listing Rules, subject to, market conditions and its capital management needs.

2. Use of Proceeds from the Global Offering and the Top-up Placing

The table below set out details of the net proceeds from the Global Offering and the Top-up Placing brought forward in the beginning of the Reporting Period:

Proceeds from the Global Offering:

	Amounts not yet utilized as of December 31, 2023	
	<i>HK\$ million</i>	<i>Percentage</i>
Key drug development programs the R&D and commercialization of KN046		
• the ongoing and planned clinical trials of, and preparation of registration filings for, KN046	140.7	43.3%
• the launch and, subject to regulatory approval, commercialization of KN046	35.2	10.8%
Subtotal	175.9	54.1%

**Amounts not yet utilized as of
December 31, 2023**
HK\$ million Percentage

the R&D and commercialization of KN026

• the ongoing and planned clinical trials of, and preparation of registration filings for, KN026	119.3	36.7%
• the launch and, subject to regulatory approval, commercialization of KN026	29.8	9.2%
<i>Subtotal</i>	<i>149.1</i>	<i>45.9%</i>
Total	325.0	100.0%

Proceeds from the Top-up Placing:

**Amounts not yet utilized as of
December 31, 2023**
HK\$ million Percentage

the R&D and commercialization

• the launch of several registered clinical trials of JSKN003	270.6	80.3%
• the clinical development of JSKN016	29.2	8.7%
<i>Subtotal</i>	<i>299.8</i>	<i>89.0%</i>
Company's general corporate purposes	37.0	11.0%
Total	336.8	100.0%

3. *Post-IPO Share Award Scheme*

As the 510,000 Award Shares granted during the Reporting Period were made out of the Shares managed by the Trustee as part of the trust fund pursuant to the Post-IPO Restricted Share Award Scheme and no Shares will be issued in respect of such Award Shares, the Company is not required for the disclosure under Rule 17.03(3) of the Listing Rules.

The additional information set out above does not affect other information contained in the 2024 Annual Report. Save as disclosed above, all other information in the 2024 Annual Report remains unchanged.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, October 13, 2025

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, Mr. CHO Man as non-executive Director, and Mr. WU Dong, Ms. WONG Yan Ki Angel and Dr. GAO Xiang as independent non-executive Directors.